支气管动脉栓塞化疗术联合盐酸安罗替尼治疗不可手术Ⅲ期的驱动基因阴性非小细胞肺癌的临床疗效  

Clinical efficacy of bronchial arterial embolization chemotherapy combined with anrotinib hydrochloride in the treatment of inoperable stageⅢdriver gene negative non-small cell lung cancer

作　　者：张瑜 李高伟[1] 侯俊 李毅[1] ZHANG Yu;LI Gaowei;HOU Jun;LI Yi(The First Department Of Oncology,Beibei Traditional Chinese Medical Hospital,Chongqing,400700,China)

机构地区：[1]重庆市北碚区中医院肿瘤一科,重庆400700

出　　处：《当代医学》2023年第12期72-76,共5页Contemporary Medicine

摘　　要：目的探究支气管动脉栓塞化疗术联合盐酸安罗替尼治疗不可手术的Ⅲ期驱动基因阴性非小细胞肺癌(NSCLC)的临床疗效。方法选取2018年6月至2019年12月本院收治的61例Ⅲ期且驱动基因阴性均不可手术切除的非小细胞肺癌患者作为研究对象,按照患者治疗意愿不同分为治疗组(n=30)与对照组(n=31)。对照组采用支气管动脉栓塞化疗术治疗,治疗组在对照组基础上联合盐酸安罗替尼口服治疗。比较两组随访情况、客观有效率、疾病控制率、无进展生存期、生命质量评分、不良事件发生情况。结果治疗组疾病控制率为86.7%,高于对照组的62.1%,差异有统计学意义(P<0.05);两组客观缓解率比较差异无统计学意义。治疗组中位无进展生存期(PFS)为(302.40±104.29)d,长于对照组的(198.41±77.69)d,差异有统计学意义(P<0.05)。两组生命质量改善、稳定、恶化率比较差异无统计学意义。两组恶心呕吐、骨髓抑制发生率比较差异无统计学意义。结论支气管动脉栓塞化疗联合盐酸安罗替尼治疗NSCLC,可有效提高驱动基因阴性的不可手术的Ⅲ期NSCLC患者的控制率,延长无进展生存期。Objective To investigate the clinical efficacy of bronchial arterial embolization chemotherapy combined with anrotinib hydrochloride in the treatment of inoperable stageⅢdriver gene negative non-small cell lung cancer(NSCLC).Methods 61 patients with NSCLC with stageⅢ,driver gene negative and unresectable from June 2018 to December 2019 were selected as the study subjects,and they were divided into treatment group(n=30)and control group(n=31)according to the patient's treatment wishes.The control group was treated with bronchial artery embolization chemotherapy,and the treatment group was combined with oral treatment of anrotinib hydrochloride on the basis of the control group.The follow-up,objective response rate,disease control rate,progression-free survival,quality of life score and adverse events were compared between the two groups.Results The disease control rate in the treatment group was 86.7%,which was higher than 62.1%in the control group,the difference was statistically significant(P<0.05).There was no significant difference in the objective remission rate between the two groups.The median progressive free survival(PFS)in the treatment group was(302.40±104.29)d,which was longer than(198.41±77.69)d in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the rate of improvement,stability and deterioration of quality of life between the two groups.There was no significant difference in the incidence of nausea,vomiting and myelosuppression between the two groups.Conclusion Bronchial artery embolization chemotherapy combined with anlotinib hydrochloride in the treatment of NSCLC can effectively improve the control rate of inoperable stageⅢNSCLC patients with negative driver genes,prolong progression-free survival.

关 键 词：安罗替尼 支气管动脉栓塞化疗 驱动基因 阴性 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]